Aklief FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
Aklief (trifarotene) is a topical retinoid indicated for the treatment of acne vulgaris in patients 9 years of age and older.
- Trifarotene is the first new retinoid approved by the FDA for the treatment of acne in over 20 years.
- Trifarotene is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.
- Aklief Cream is the first topical treatment specifically studied and proven to treat both facial acne (forehead, cheeks, nose and chin) and truncal acne (chest, shoulders and back).
- Aklief Cream is applied thinly to the affected areas of the face and/or trunk once a day in the evening.
- Common side effects include application site irritation, application site pruritus (itching), and sunburn.
Development Timeline for Aklief
|Oct 4, 2019||Approval FDA Approves Aklief (trifarotene) Cream, a New Topical Retinoid for the Treatment of Acne|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.